Amyris, Inc. (Emeryville, Calif.) said it will acquire Oobli Inc. (Davis, Calif.), a developer of fermentation-based sweet proteins that food and beverage brands use to reduce sugar without giving up taste.
The integrated biomanufacturing company described the deal as a commercial and technology expansion rather than a simple capacity addition. It pairs Amyris' scientific base and manufacturing depth with Oobli's protein fermentation expertise, and follows the capacity increase Amyris completed earlier this year at its advanced fermentation facility in Barra Bonita, Brazil. Amyris said the move accelerates its position in protein- and peptide-based solutions across its end markets.
Platform and product portfolio
Oobli's commercial sweet proteins are expected to be the first products to benefit from the combined platform. The company has spent roughly a decade refining a fermentation route to sweet proteins that occur naturally in rare fruits and berries growing near the equator, and its ingredients are described as the first of their kind in the sugar-reduction category.
According to the companies, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes. The portfolio covers three ingredients: Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin. They hold FDA GRAS status as an ingredient and are FEMA GRAS-affirmed for use as a natural flavor.
With consumer awareness of metabolic health and sugar reduction growing, the companies see sweet proteins as an additional tool for brands across a broad set of categories:
- sports and nutrition products and dairy
- beverages
- chocolate, bakery and confectionery
How the two sides frame the deal
Chief executive Kathy Fortmann said Oobli provides a commercial and technology platform that complements Amyris' own, and that combining Oobli's protein expertise with Amyris' strain engineering, manufacturing scale and commercial reach could extend its capabilities in food and beverage, personal care, flavor and fragrance, and agriculture. She added that biomanufactured solutions succeed when they align with consumer demand and market needs, and that Oobli's platform addresses sweet taste, sugar reduction and clean label together.
Oobli chief executive Ali Wing said her company had long held that there is a better way to deliver the sweet taste consumers want without trade-offs to health and the environment, and that joining Amyris gives it the scale and resources to pursue its aim of making sweet proteins a standard for sweetness.
Timing and continuity
The acquisition is expected to close within the coming weeks. The companies said all existing customer commitments and brand partnerships would continue to be honored without interruption as the sweet protein portfolio is folded into Amyris.
